ArticleBiosensors & bioelectronics2021
Accessible detection of SARS-CoV-2 through molecular nanostructures and automated microfluidics.
Article in Biosensors & bioelectronics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Magnetic augmentation through multi-gradient coupling enables direct and programmable profiling of circulating biomarkers.Nature communications · 2024Article
- Extended Review Concerning the Integration of Electrochemical Biosensors into Modern IoT and Wearable Devices.Biosensors · 2024Review
- Multiplexed RNA profiling by regenerative catalysis enables blood-based subtyping of brain tumors.Nature communications · 2023Article
- Accurate quantification of DNA using on-site PCR (osPCR) by characterizing DNA amplification at single-molecule resolution.Nucleic acids research · 2023Article
- Internet-of-medical-things integrated point-of-care biosensing devices for infectious diseases: Toward better preparedness for futuristic pandemics.Bioengineering & translational medicine · 2023Review
- Programmable Nanostructures Based on Framework-DNA for Applications in Biosensing.Sensors (Basel, Switzerland) · 2023Review
- Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions.Biomedical microdevices · 2023Review
- A hydrogel-based mechanical metamaterial for the interferometric profiling of extracellular vesicles in patient samples.Nature biomedical engineering · 2023Article
- Microfluidics for COVID-19: From Current Work to Future Perspective.Biosensors · 2023Review
- Device integration of electrochemical biosensors.Nature reviews bioengineering · 2023Review
- Review
- Design and simulation of a millifluidic device for differential detection of SARS-CoV-2 and H1N1 based on triboelectricity.Bioelectrochemistry (Amsterdam, Netherlands) · 2022Article
- Isothermal amplification-assisted diagnostics for COVID-19.Biosensors & bioelectronics · 2022Review
- Microfluidics Technology in SARS-CoV-2 Diagnosis and Beyond: A Systematic Review.Life (Basel, Switzerland) · 2022Review
- Microfluidics-Based Biosensing Platforms: Emerging Frontiers in Point-of-Care Testing SARS-CoV-2 and Seroprevalence.Biosensors · 2022Review
- Recent advances in PCR-free nucleic acid detection for SARS-COV-2.Frontiers in bioengineering and biotechnology · 2022Review
- Nucleic acid testing of SARS-CoV-2: A review of current methods, challenges, and prospects.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate and accessible nucleic acid diagnostics is critical to reducing the spread of COVID-19 and resuming socioeconomic activities. Here, we present an integrated platform for the direct detection of SARS-CoV-2 RNA targets near patients. Termed electrochemical system integrating reconfigurable enzyme-DNA nanostructures (eSIREN), the technology leverages responsive molecular nanostructures and automated microfluidics to seamlessly transduce target-induced molecular activation into an enhanced electrochemical signal. Through responsive enzyme-DNA nanostructures, the technology establishes a molecular circuitry that directly recognizes specific RNA targets and catalytically enhances signaling; only upon target hybridization, the molecular nanostructures activate to liberate strong enzymatic activity and initiate cascading reactions. Through automated microfluidics, the system coordinates and interfaces the molecular circuitry with embedded electronics; its pressure actuation and liquid-guiding structures improve not only analytical performance but also automated implementation. The developed platform establishes a detection limit of 7 copies of RNA target per μl, operates against the complex biological background of native patient samples, and is completed in <20 min at room temperature. When clinically evaluated, the technology demonstrates accurate detection in extracted RNA samples and direct swab lysates to diagnose COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.